Filing Details
- Accession Number:
- 0001735276-23-000009
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-02-14 16:03:39
- Reporting Period:
- 2023-02-10
- Accepted Time:
- 2023-02-14 16:03:39
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1178670 | Alnylam Pharmaceuticals Inc. | ALNY | Pharmaceutical Preparations (2834) | 770602661 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1458494 | Akshay Vaishnaw | 675 West Kendall Street Henri A. Termeer Square Cambridge MA 02142 | President | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2023-02-10 | 30,913 | $63.00 | 53,014 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2023-02-10 | 1,709 | $213.13 | 51,305 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2023-02-10 | 2,307 | $214.28 | 48,998 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2023-02-10 | 10,279 | $215.59 | 38,719 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2023-02-10 | 19,447 | $216.38 | 19,272 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2023-02-10 | 4,302 | $217.05 | 14,970 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2023-02-10 | 30,913 | $0.00 | 30,913 | $63.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2023-12-18 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 515 | Indirect | by Managed Account |
Footnotes
- All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2022.
- The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $212.71 to $213.70. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $213.72 to $214.66. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $214.88 to $215.88. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $215.89 to $216.89. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $216.96 to $217.31. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.
- The stock option vested as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter.
Billionaire Hedge Funds
